

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	5918147
<b>Application Number:</b>	10828469
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	5223
<b>Title of Invention:</b>	TISSUE RECONFIGURATION
<b>First Named Inventor/Applicant Name:</b>	Michael D. Laufer
<b>Customer Number:</b>	81353
<b>Filer:</b>	Giordana Marie Belenchia
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	100873-273 (END6430USCNT8
<b>Receipt Date:</b>	19-AUG-2009
<b>Filing Date:</b>	21-APR-2004
<b>Time Stamp:</b>	16:16:40
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$810
RAM confirmation Number	2434
Deposit Account	141449
Authorized User	BELENCHIA-SAUER,GIORDANA M.

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed (SB/08)	SB08_273.PDF	608894	no	7
			04de1e3cf4bb1e29ac1bf92635b913a59e97fa67		
Warnings:					
Information:					
2	Foreign Reference	EP0593920A1.pdf	1086481	no	21
			e7105fd4788bbfd867138ce559ecb1ca0ea84839		
Warnings:					
Information:					
3	Foreign Reference	JP2000254143A.pdf	302029	no	6
			816ceb6fcd0a6b3d90359253d8154c3ebe8fa08d		
Warnings:					
Information:					
4	NPL Documents	JapaneseOAforApplicationNo2005122394.pdf	77165	no	2
			c855aa8ce15bd33e2748019dbecb725178f40bc		
Warnings:					
Information:					
5	Request for Continued Examination (RCE)	RCE_273.PDF	697191	no	3
			6408e065f3c71cb270dd12e077999696d3cf3b7a		
Warnings:					
Information:					
6	Fee Worksheet (PTO-875)	fee-info.pdf	30405	no	2
			e8689ef4c482ee6fd312794da7a76147dc221fa5		
Warnings:					
Information:					
Total Files Size (in bytes):			2802165		

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**